Chris Holman, Professor at the University of Missouri-Kansas City School of Law and author of Holman’s Biotech IP Blog, recently posted a great summary of the patent provisions in the follow-on biologics bill currently under consideration in Congress.
You can read Holman’s post here.
Filed under: Follow-on Biologics | Tagged: Follow-on Biologics |
Patently BIOtech 
Leave a Reply